Login / Signup

Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases.

Fabian SpethJohannes-Peter HaasClaas H Hinze
Published in: Pediatric rheumatology online journal (2016)
This is a case series and data were retrospectively registered.
Keyphrases
  • recombinant human
  • high dose
  • low dose
  • stem cell transplantation
  • electronic health record
  • big data
  • disease activity
  • artificial intelligence
  • data analysis